September 08, 2020

Deal Drivers in Healthcare and Life Sciences Mainland China: M&A and IPO Trends in H1 2020 and beyond

Virtual briefing in partnership with Mergermarket, an Acuris company

DATE: 9 September 2020

TIME: 11:00 Beijing

Not only the cause for the most profound economic crisis since the Global Financial Crisis, but COVID-19 was also a wake-up call to better prepare for global pandemics and public health emergencies. After several years’ growth in the Greater China region, Healthcare and life science sector are firm back under the spotlight, as being one of the most resilient industries in investment and M&A.

  • Unlike the M&A slump in major traditional sectors, biotech in China and Hong Kong enjoyed a 78% year-on-year growth in M&A deal value in 1H 2020, as well as being the most robust subsector to recover in 2Q
  • The biotech listing boom in HKEX remains and was further fueled by dual-listing candidates from NYSE or Shanghai’s STAR board. Pharma, Medical and Biotech together recorded 67 deals worth USD 6.9bn in 1H

In this live panel discussion with China Everbright, I-Mab and Fangda Partners we take stock of M&A and IPOs in Mainland China and consider the areas where financial stress is of greatest concern, as well as opportunities to be sought after.

Unable to join the live session? Register now to access the on-demand replay after the webinar.

 

You may also like:

Dealmakers Dialogues: How Saudi Arabia’s growth is cementing its position as an M&A leader in 2023

Q4 Corporate Update | Dealmakers debrief on 2022

Join us on Thursday, December 8 at 2 p.m. ET / 11 a.m. PT for the final installment of our 2022 quarterly roundtable series during this live webinar to hear what's on the minds of our expert panelists as we look ahead at 2023.

1344913240
What are the prospects for European M&A in 2023?

The Financial Times – in partnership with Datasite – will provide a key forward-looking market outlook for the EMEA M&A market and explore the risks and opportunities that this new dealmaking environment presents.

© 2022 Datasite All rights reserved

Datasite provides secure software solutions for managing the full spectrum of financial transactions — including M&A, restructuring & administration, and capital raising. Our intuitive platform offers ironclad security enabling file sharing and collaboration within and across organizations. More than a virtual data room (VDR), Datasite supports advisors and their clients across the entire deal lifecycle with secure collaborative software that shortens timelines for buy-side and sell-side teams from deal sourcing and deal preparation to post-merger integration (PMI) while meeting regulatory compliance — including GDPR and CCPA requirements. As the premiere virtual data room for M&A due diligence globally, Datasite is consistently recognized for breakthrough technologies like our AI/ML-enabled capabilities and automated redaction tools. Beyond due diligence, Datasite provides transaction and document management solutions for investment banks, corporate development, private equity, and law firms across industries.